Skip to Main content Skip to Navigation
New interface
Journal articles

Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment

Abstract : Vascular endothelial growth factor A is known to play a central role in tumor angiogenesis. Several studies showed that VEGF-A is also an immunosuppressive factor. In tumorbearing hosts, VEGF-A can modulate immune cells (DC, MDSC, TAM) to induce the accumulation of regulatory T-cells while simultaneously inhibiting T-cell functions. Furthermore, VEGFR-2 expression on activated T-cells and FoxP3 high regulatory T-cells also allow a direct effect of VEGF-A. Anti-angiogenic agents targeting VEGF-A/VEGFR contribute to limit tumor-induced immunosuppression. Based on interesting preclinical studies, many clinical trials have been conducted to investigate the efficacy of anti-VEGF-A/VEGFR treatments combined with immune checkpoint blockade leading to the approvement of these associations in different tumor locations. In this review, we focus on the impact of VEGF-A on immune cells especially regulatory and effector T-cells and different therapeutic strategies to restore an antitumor immunity.
Document type :
Journal articles
Complete list of metadata
Contributor : Magali TERME Connect in order to contact the contributor
Submitted on : Monday, September 26, 2022 - 5:02:00 PM
Last modification on : Wednesday, September 28, 2022 - 5:29:24 AM


Publication funded by an institution




Morgane Bourhis, Juliette Palle, Isabelle Galy-Fauroux, Magali Terme. Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment. Frontiers in Immunology, 2021, 12, pp.616837. ⟨10.3389/fimmu.2021.616837⟩. ⟨hal-03788530⟩



Record views


Files downloads